Clobetasol Propionate vs. Tacrolimus

Overview

Mechanism of Action

Indications (Approved & Off-Label)

• Psoriasis (plaques, scalp)
• Lichen planus (including erosive oral lichen planus)
• Lichen sclerosus (vulvar — first-line; 0.05% ointment daily × 3 months, then taper)
• Alopecia areata
• Bullous pemphigoid
• Discoid lupus erythematosus

• Moderate-to-severe atopic dermatitis (0.1% adults; 0.03% children ≥2 yrs)
• Off-label: seborrheic dermatitis, cutaneous lupus, vitiligo, pyoderma gangrenosum, oral/perineal Crohn's disease, oral lichen planus
• Used as a steroid-sparing agent when long-term therapy is needed on the face, eyelids, or intertriginous areas

Pharmacokinetics

Adverse Effects

Clobetasol (local — related to potency and duration)

• Skin atrophy, striae, telangiectasias, skin fragility, purpura
• Perioral dermatitis, steroid rosacea (especially with facial use)
• Acne, hypertrichosis
• Hypopigmentation
• Secondary infection susceptibility
• HPA axis suppression → iatrogenic Cushing syndrome, adrenal insufficiency (especially in children with >50% BSA involvement)
• Growth retardation in children
• Tachyphylaxis with prolonged use
• Steroid withdrawal syndrome — rebound erythema, burning, swelling upon discontinuation (especially on face)

Tacrolimus (topical)

• Application site stinging and burning — most common, especially on excoriated skin; usually transient (attenuated by pretreating with topical steroid, refrigerating ointment, or premedication with aspirin)
• Exacerbation of rosacea (including granulomatous subtype) — use with caution
• Increased risk of eczema herpeticum in atopic patients
• No skin atrophy, striae, or HPA suppression — major advantage over corticosteroids
• FDA black box warning: theoretical risk of lymphoma and skin malignancy with long-term use (based on systemic immunosuppression data and animal studies); avoid on premalignant skin, infected skin, or in patients receiving phototherapy
• Should not be used in Netherton syndrome

Key Clinical Comparisons

Atopic Dermatitis (primary battleground)

• Tacrolimus 0.1% is equivalent to mid-potency topical steroids in efficacy for AD
• Tacrolimus is preferred for face, eyelids, neck, and intertriginous areas — where clobetasol is generally contraindicated due to atrophy risk
• Clobetasol is used for short-term control of severe, lichenified plaques on the trunk/extremities
• Tacrolimus enables safe long-term maintenance without atrophy — particularly valuable in children

Oral Lichen Planus

Alopecia Areata

Lichen Sclerosus (Vulvar)

Practical Prescribing Guide

Summary

Clobetasol Propionate for Alopecia Areata — Dosage & Guidelines

Where Does Clobetasol Fit?

• Intralesional triamcinolone remains first-line for limited adult disease (solitary/few patches)
• Topical clobetasol is the first-line topical option and first-line overall in children and patients unsuitable for injections

Dosage Protocols

Adults — Scalp & Body Patches

The 6-weeks-on / 6-weeks-off pulse protocol is the key feature — continuous daily use causes tachyphylaxis and skin atrophy. The BAD 2024 living guideline specifically recommends this cycling approach.

Children — Scalp AA

• Clobetasol 0.05% cream, twice daily
• Two cycles of 6 weeks ON / 6 weeks OFF
• Result: 85% achieved ≥50% hair regrowth at 24 weeks vs. 33.3% with hydrocortisone 1% (P <0.001)

⚠️ Not recommended in children under 12 years for scalp solution/foam formulation (safety data limited). Use under specialist supervision.

Specific Anatomical Sites

When to Step Up Treatment

Safety Limits & Monitoring

• Maximum continuous use: 2–4 weeks for scalp solution/foam without a break; use the 6-on/6-off cycle for longer courses
• Watch for: scalp atrophy, folliculitis, telangiectasia, HPA suppression (especially children, large BSA)
• On the face/eyebrows: limit application duration and frequency; risk of glaucoma from periocular use — ophthalmology review if used near eyes
• If no response after 2 full cycles (24 weeks): reassess — step up to intralesional, systemic therapy, or JAK inhibitor

Adjunct Combination

• Topical minoxidil 5% (once daily separately) — synergistic for hair regrowth
• Intralesional triamcinolone for stubborn areas within a predominantly topical regimen

Eyebrow Loss in Alopecia Areata — Best Treatments

First-Line: Intralesional Triamcinolone Acetonide

⚠️ Critical safety note for eyebrows: Use low concentrations (≤5 mg/mL) and small volumes. Higher concentrations or deeper injections risk subcutaneous fat atrophy (brow depression) and, very rarely, retinal artery embolization — avoid injecting under significant pressure or with a small-bore syringe.

Second-Line / Adjunct Options

Topical Clobetasol 0.05%

• Applied once daily (not twice daily — eyebrow skin is thin)
• Use a small amount along the brow ridges
• 6 weeks ON / 6 weeks OFF cycle
• Less effective than intralesional TA for the brow, but useful when injections are refused or in children
• Avoid getting into eyes — risk of periocular absorption → glaucoma/cataract

Prostaglandin Analogues (Bimatoprost / Latanoprost)

• Originally glaucoma drops; FDA-approved bimatoprost 0.03% (Latisse) for eyelash growth — used off-label for eyebrows
• Applied once nightly to the brow line with a fine brush/cotton tip
• Mechanism: prolongs anagen phase, increases follicular melanogenesis
• Evidence in AA is mixed — works better for cosmetic thinning than complete brow loss from AA
• Side effects: periocular pigmentation, iris color change (brown pigmentation with prolonged use), skin darkening at application site

Topical Minoxidil 2–5%

• Adjunct — used in combination with other modalities
• Applied once daily to brow area
• Modest effect when used alone; useful to prevent relapse

Topical Tacrolimus 0.1%

• Off-label; useful when topical steroid side effects are a concern
• Once daily; no atrophy risk

Systemic Options (for Eyebrow Loss with Extensive AA)

Practical Approach by Severity

Isolated eyebrow loss (1-2 brows)
  → Intralesional TA 2.5 mg/mL q4-6 weeks  ← FIRST-LINE
  → Add: topical bimatoprost nightly (off-label)
  → Add: topical minoxidil 2% once daily

Eyebrow loss + patchy scalp AA
  → Intralesional TA for brows
  → Topical clobetasol (6on/6off) for scalp patches

Eyebrow + eyelash + extensive scalp loss (SALT ≥50)
  → Oral JAK inhibitor (baricitinib 4 mg or ritlecitinib 50 mg)
  → Expect eyebrow/eyelash improvement as systemic disease responds

Key Points

• Intralesional TA is the most reliable treatment for isolated eyebrow loss — more effective than topical agents alone
• Use low concentrations (2.5 mg/mL) in the brow to minimize atrophy risk
• Bimatoprost is a reasonable adjunct nightly application — but limited AA-specific evidence
• If eyebrow loss is part of severe systemic AA, JAK inhibitors offer the best current evidence for whole-body hair regrowth including brows and lashes